Physician profile
Tara Ralph
NPI 1184048795
$8,356.53
in general payments reported to CMS, 2019-2025
43 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $380 · 2021: $783 · 2022: $839 · 2023: $1,771 · 2024: $1,923 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,566.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,172.13 | 2021-2025 | |
| Astellas Pharma US INC | $842.63 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $587.14 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $444.22 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $346.75 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $340.71 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $340.40 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.97 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Pfizer INC. | $266.55 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $218.19 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $147.34 | 2023-2025 | |
| Exact Sciences Corporation | $140.73 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $138.29 | 2025 | Auvelity, Symbravo |
| Shield Therapeutics INC | $131.20 | 2023-2025 | Accrufer |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Ralph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.